Pharmaceutical

EC approves AstraZeneca’s Fasenra for EGPA treatment

The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.

Oct 30, 2024 - 04:00
EC approves AstraZeneca’s Fasenra for EGPA treatment
The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.
Read the original article

Tags:

Previous Article

US Border Protection warns pharma of risks with incorrect biologic importation

Next Article

South Korean pricing reform suggests more flexible drug reimbursement negotiations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market

STAT+: New congressional bill would thwart patent thick...

Jan 12, 2024

Almirall completes EU regulatory procedure for antifungal Jublia

Almirall completes EU regulatory procedure for antifung...

Oct 16, 2024

Prometheus’ PRA023 could address an immediate need in Crohn’s Disease treatment

Prometheus’ PRA023 could address an immediate need in C...

Mar 23, 2023